The conversation about physician burnout has been loud for years. But a quietly powerful data story that emerged at the ADA 2026 Scientific Sessions last week deserves more spotlight than it received: pharmacists embedded into refill authorization workflows are not just catching safety issues. They are measurably relieving provider burnout while simultaneously improving patient outcomes in health systems that have implemented the model.
The University Hospitals Model and the Data Behind It
Pharmacist-led refill authorization models have shown significant promise in reducing provider workload and improving patient care, according to data presented by Richie A. Romaniszyn, PharmD, BCPS, operations coordinator at University Hospitals in Cleveland, Ohio. In response to persistent physician burnout and growing refill backlogs in high volume outpatient clinics, University Hospitals implemented a centralized model in which pharmacists assumed responsibility for processing medication refill requests. By triaging refills through a structured appropriateness, safety, and efficacy review, pharmacists were able to ensure timely medication access, identify clinical concerns, and provide adherence support; tasks often difficult for healthcare providers to complete amid heavy inbox and visit burdens. This shift not only improved operational efficiency but also strengthened patient-provider relationships by reducing delays and frustration associated with medication access.
The structural insight is important: this is not a pilot project at one hospital. It is a model with a documented implementation framework that other health systems can replicate, and the operational logic behind it is applicable at any scale from a single-prescriber clinic to a multi-site academic health system.
Why Physician Inbox Overload Is the Crisis Enabling This Model
To understand why the pharmacist-led refill model is gaining momentum, you need to understand the severity of what it is solving.
Physicians in high-volume outpatient clinics typically manage enormous electronic inbox volumes alongside direct patient care. Refill authorization requests are among the most time-consuming inbox tasks, because each one technically requires clinical judgment: Is the current dose appropriate? Have labs been checked recently? Is the patient adherent? Is a monitoring parameter overdue? Are there any new prescriptions that interact with this refill?
In practice, most of those questions go unanswered. The prescriber clicks “approve” to manage the queue. The refill goes out. The clinical review that should accompany it doesn’t happen.
Increasing administrative workload is linked with lower quality of patient care and physician burnout. Pharmacist managed refill services may improve provider workload measures and clinical outcomes. Under collaborative practice agreements, pharmacists can address refill requests and recommend interventions. Turnaround time within two business days for the large majority of requests indicates efficiency of this process, and demonstrates potential to positively affect medication adherence and persistence. Workflow changes associated with a pharmacist-managed refill service may translate to increased face-to-face patient interactions for physicians, as administrative burden decreases.
Refill services have been found to increase patient satisfaction and reduce physician workload. Models involving pharmacists have demonstrated the potential to improve provider perception of burnout, and to reduce delays and errors in patient care.
The refill that goes out without clinical review is the refill that misses an overdue hemoglobin A1C check, an interaction with a newly prescribed medication, or an adherence gap that signals a patient who needs outreach. The pharmacist-led model catches all three.
What the Refill Review Actually Looks Like in Practice
The University Hospitals model is built around a structured triage framework that every pharmacist in any outpatient or health system setting can adapt.
Each incoming refill request is evaluated against three questions before authorization proceeds. First, appropriateness: is this medication still clinically indicated for this patient, at this dose, at this point in their disease course? Second, safety: are there active drug-drug interactions, lab values that warrant dose adjustment, or monitoring parameters that are overdue? Third, efficacy: is there evidence that this medication is working, and is the patient adherent enough for the refill to be clinically meaningful?
If the answer to all three is yes, the pharmacist authorizes the refill and documents the review. If any question generates a concern, the pharmacist either addresses it directly under a collaborative practice agreement or routes a specific, actionable communication to the prescriber, describing the concern and the recommended response.
That structured documentation transforms what was a passive administrative click into a clinical record. And clinical records are the foundation of billing, quality reporting, and value-based care performance.
The Billing and Quality Dimension Most Health Systems Are Missing
Every refill that passes through a pharmacist’s structured clinical review is three things simultaneously: a patient safety checkpoint, a medication adherence support touchpoint, and a documentable clinical activity.
Health systems that implement pharmacist-led refill authorization programs and then fail to document the clinical interventions are leaving value on the table. The pharmacist who identifies a drug interaction, adjusts a dose, or flags an overdue monitoring parameter during a refill review has performed a medication therapy management activity. In the right billing infrastructure, that activity is compensable.
More broadly, the Stars and HEDIS quality metrics covered in a prior issue of this newsletter measure exactly the outcomes this model improves. Medication adherence for diabetes, hypertension, and cardiovascular medications are direct Stars measures. The pharmacist-led refill model, by ensuring appropriate refills go out on time with clinical review, directly supports adherence rates that improve Stars performance. Health plans that tie Stars performance to pharmacy incentives are, in effect, paying for this model’s outcomes already. The pharmacies and health systems that can document the connection will capture those incentives. The ones that can’t will watch the value flow elsewhere.
The Physician Burnout Data That Creates the Partnership Opportunity
Workload was identified as the primary driver of burnout among hospitalists in a quality improvement initiative at Huntington Hospital. Following workflow redesign that delegated administrative tasks to the appropriate team member within their scope of practice, burned-out clinicians reported measurable relief from the specific tasks that drove the highest distress. The data consistently points to the same intervention: identify which high-volume administrative tasks are within the scope of another trained professional, and systematically delegate them with appropriate oversight.
Refill authorization is the most obvious example in outpatient medicine. It is high-volume, repetitive, requires clinical judgment but not necessarily physician-level judgment for most requests, and consumes inbox time that physicians consistently report as a primary burnout driver.
The pharmacist who walks into a conversation with a clinic director or medical director and says “I can take your refill inbox load, process it through a structured clinical review under a collaborative practice agreement, and give you back two hours of clinical time per week” is not proposing a cost center. They are proposing a burnout intervention with a documented evidence base and a measurable operational return.
That conversation, backed by the University Hospitals data and the published literature on pharmacist-managed refill services, is the clinical partnership pitch that builds the kind of health system integration that makes pharmacist roles permanent, not project-based.
The Specific Drug Categories Where This Matters Most
Not all refill requests carry the same clinical complexity. The highest-value targets for pharmacist-led review are the drug categories where inappropriate refills create the most risk and where clinical review catches the most actionable concerns.
Diabetes medications, particularly insulin regimens and GLP-1 therapies, warrant specific attention to A1C trends, hypoglycemia patterns from CGM data when available, and dose appropriateness relative to current weight and renal function.
Psychiatric medications, including antidepressants, antipsychotics, and mood stabilizers, require review for adherence patterns, monitoring labs where applicable, and the deprescribing conversations now supported by the new CMS billing guidance covered in a prior issue of this newsletter.
Cardiovascular medications, ACE inhibitors, ARBs, beta-blockers, and diuretics, require monitoring of renal function and electrolytes, particularly in patients also on SGLT2 inhibitors or finerenone, where potassium and eGFR trends are clinically essential.
Anticoagulants, even direct oral anticoagulants that don’t require INR monitoring, warrant review of drug interactions, renal dose adjustments, and adherence patterns that predict bleeding or thromboembolic risk.
In each of these categories, the pharmacist reviewing the refill request adds clinical value that the click-and-approve approach entirely misses.
Your Action This Week
Identify the highest-volume refill categories in your practice or health system. Calculate how many refill authorization requests hit the prescriber inbox monthly in each category. Then calculate the average time a prescriber spends per request, typically two to five minutes for a routine refill.
The product of those two numbers is the monthly physician time your pharmacy team could recover through a structured pharmacist-led refill model. For a clinic processing 200 refill requests per month at three minutes each, the math produces 10 physician hours monthly, or roughly $1,500 to $2,500 in physician time at median compensation rates.
Present that calculation to a clinic director or medical director. Then propose a 90-day pilot under a collaborative practice agreement in which pharmacists handle refill authorizations for two or three defined drug categories, with full documentation and a structured escalation protocol for cases requiring physician judgment.
The University Hospitals model generated data that is now being presented at the ADA Scientific Sessions. Your pilot generates the data for your institution. The institutions that build this infrastructure in 2026 will have a documented, replicable model when payers begin tying refill accuracy and adherence rates to quality bonuses.
The physician inbox is overflowing. The pharmacist has the training to take the clinical burden off it. The data says this works. Build the model before your competitor does.
Sources: Pharmacy Times (Recapping 2025 ASHP Midyear: Expanding the Pharmacist’s Role in Patient Care, Technology, and Health System Resilience, December 2025), ResearchGate / JACCP (Development and Implementation of a Centralized Comprehensive Refill Authorization Program in an Academic Health System), PMC / Cureus (Reducing Physician Burnout Through Workflow Redesign: A Quality Improvement Initiative), Frontiers in Public Health (Pharmacist Burnout: From Coping to System Accountability in the Medication-Use Process, January 2026), PMC / JAMDA (Pharmacist-Managed Refill Service Impacts on Clinician Workload and Medication Interventions in a Federally Qualified Health Center), Pharmacy Times (ADA 2026 Scientific Sessions Pharmacist Data Coverage, June 2026)